Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Sell
6
IFRX Quote, Financials, Valuation and Earnings
Last price:
$0.80
Seasonality move
:
-16.46%
Day range:
$0.80 - $0.85
52-week range:
$0.71 - $2.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
265.10x
P/B ratio:
0.71x
Volume:
523K
Avg. volume:
583.3K
1-year change:
-43.88%
Market cap:
$54.4M
Revenue:
$179.4K
EPS (TTM):
-$0.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$36.3K | -$0.20 | 256.48% | -10.49% | $3.62 |
|
CDT
Conduit Pharmaceuticals
|
-- | -- | -- | -- | -- |
|
LENZ
LENZ Therapeutics
|
-- | -$0.32 | -- | -26.67% | $44.63 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics
|
-- | -$0.63 | 25% | -1571.33% | $25.00 |
|
ORKA
Oruka Therapeutics
|
-- | -$0.48 | -- | -42.18% | $39.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$0.80 | $3.62 | $54.4M | -- | $0.00 | 0% | 265.10x |
|
CDT
Conduit Pharmaceuticals
|
$3.25 | -- | $2.6M | -- | $0.00 | 0% | -- |
|
LENZ
LENZ Therapeutics
|
$29.53 | $44.63 | $831.2M | -- | $1.03 | 0% | -- |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MAZE
Maze Therapeutics
|
$12.17 | $25.00 | $521.2M | -- | $0.00 | 0% | -- |
|
ORKA
Oruka Therapeutics
|
$11.85 | $39.50 | $443.7M | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IFRX
InflaRx NV
|
-- | 4.290 | -- | 3.85x |
|
CDT
Conduit Pharmaceuticals
|
-- | 2.365 | -- | -- |
|
LENZ
LENZ Therapeutics
|
-- | 0.772 | -- | -- |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
MAZE
Maze Therapeutics
|
-- | 0.000 | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -0.428 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
-$9.8K | -$13.7M | -56.78% | -56.78% | 1207051.66% | -$14.8M |
|
CDT
Conduit Pharmaceuticals
|
-- | -$4M | -- | -- | -- | -$4.3M |
|
LENZ
LENZ Therapeutics
|
-- | -$16.9M | -- | -- | -- | -$16.2M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -$25.1M | -- | -- | -- | -$20.9M |
InflaRx NV vs. Competitors
-
Which has Higher Returns IFRX or CDT?
Conduit Pharmaceuticals has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Conduit Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M CDTConduit Pharmaceuticals-- -$19.80 -- -
What do Analysts Say About IFRX or CDT?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 350.85%. On the other hand Conduit Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that InflaRx NV has higher upside potential than Conduit Pharmaceuticals, analysts believe InflaRx NV is more attractive than Conduit Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 CDTConduit Pharmaceuticals0 0 0 -
Is IFRX or CDT More Risky?
InflaRx NV has a beta of 1.572, which suggesting that the stock is 57.18% more volatile than S&P 500. In comparison Conduit Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or CDT?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Conduit Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Conduit Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or CDT?
InflaRx NV quarterly revenues are -$450, which are larger than Conduit Pharmaceuticals quarterly revenues of --. InflaRx NV's net income of -$8.7M is lower than Conduit Pharmaceuticals's net income of -$5.1M. Notably, InflaRx NV's price-to-earnings ratio is -- while Conduit Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 265.10x versus -- for Conduit Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV265.10x -- -$450 -$8.7M CDTConduit Pharmaceuticals-- -- -- -$5.1M
-
Which has Higher Returns IFRX or LENZ?
LENZ Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat LENZ Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M LENZLENZ Therapeutics-- -$0.53 -- -
What do Analysts Say About IFRX or LENZ?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 350.85%. On the other hand LENZ Therapeutics has an analysts' consensus of $44.63 which suggests that it could grow by 51.12%. Given that InflaRx NV has higher upside potential than LENZ Therapeutics, analysts believe InflaRx NV is more attractive than LENZ Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 LENZLENZ Therapeutics5 0 0 -
Is IFRX or LENZ More Risky?
InflaRx NV has a beta of 1.572, which suggesting that the stock is 57.18% more volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or LENZ?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. InflaRx NV pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or LENZ?
InflaRx NV quarterly revenues are -$450, which are larger than LENZ Therapeutics quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than LENZ Therapeutics's net income of -$14.6M. Notably, InflaRx NV's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 265.10x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV265.10x -- -$450 -$8.7M LENZLENZ Therapeutics-- -- -- -$14.6M
-
Which has Higher Returns IFRX or LIMN?
Liminatus Pharma has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About IFRX or LIMN?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 350.85%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that InflaRx NV has higher upside potential than Liminatus Pharma, analysts believe InflaRx NV is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 LIMNLiminatus Pharma0 0 0 -
Is IFRX or LIMN More Risky?
InflaRx NV has a beta of 1.572, which suggesting that the stock is 57.18% more volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or LIMN?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or LIMN?
InflaRx NV quarterly revenues are -$450, which are larger than Liminatus Pharma quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than Liminatus Pharma's net income of --. Notably, InflaRx NV's price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 265.10x versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV265.10x -- -$450 -$8.7M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns IFRX or MAZE?
Maze Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Maze Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M MAZEMaze Therapeutics-- -- -- -
What do Analysts Say About IFRX or MAZE?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 350.85%. On the other hand Maze Therapeutics has an analysts' consensus of $25.00 which suggests that it could grow by 105.42%. Given that InflaRx NV has higher upside potential than Maze Therapeutics, analysts believe InflaRx NV is more attractive than Maze Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 MAZEMaze Therapeutics3 0 0 -
Is IFRX or MAZE More Risky?
InflaRx NV has a beta of 1.572, which suggesting that the stock is 57.18% more volatile than S&P 500. In comparison Maze Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or MAZE?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Maze Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Maze Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or MAZE?
InflaRx NV quarterly revenues are -$450, which are larger than Maze Therapeutics quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than Maze Therapeutics's net income of --. Notably, InflaRx NV's price-to-earnings ratio is -- while Maze Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 265.10x versus -- for Maze Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV265.10x -- -$450 -$8.7M MAZEMaze Therapeutics-- -- -- --
-
Which has Higher Returns IFRX or ORKA?
Oruka Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M ORKAOruka Therapeutics-- -$0.40 -- -
What do Analysts Say About IFRX or ORKA?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 350.85%. On the other hand Oruka Therapeutics has an analysts' consensus of $39.50 which suggests that it could grow by 233.33%. Given that InflaRx NV has higher upside potential than Oruka Therapeutics, analysts believe InflaRx NV is more attractive than Oruka Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 ORKAOruka Therapeutics7 0 0 -
Is IFRX or ORKA More Risky?
InflaRx NV has a beta of 1.572, which suggesting that the stock is 57.18% more volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.252, suggesting its less volatile than the S&P 500 by 74.841%.
-
Which is a Better Dividend Stock IFRX or ORKA?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. InflaRx NV pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or ORKA?
InflaRx NV quarterly revenues are -$450, which are larger than Oruka Therapeutics quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than Oruka Therapeutics's net income of -$21M. Notably, InflaRx NV's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 265.10x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV265.10x -- -$450 -$8.7M ORKAOruka Therapeutics-- -- -- -$21M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Dell Stock Be in 5 Years?
So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…
Where Will Cameco Stock Be in 5 Years?
Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 47x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
82
SBET alert for May 31
SharpLink Gaming [SBET] is down 3.17% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Buy
56
SVT alert for May 31
Servotronics [SVT] is up 0.17% over the past day.
